The year brought more FDA approvals for molecularly targeted drugs and NGS tests for personalizing cancer treatment, but reimbursement remained a stress point for industry.
The project has identified carrier variants in 109 infants so far — a total of 232 variants in 166 genes — according to a presentation at ASHG today.
According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
MyGene2 holds cases from 1,225 families, submitted by 880 user accounts, which include 723 unique genes, among them many new disease genes.
The statement recommends that germline genome editing in humans not culminate in pregnancy, but supports in vitro research into potential clinical applications.
Any short-term gains the bill may have on encouraging healthier lifestyles wouldn’t be worth the crippling effects it could have on the genomics field, leaders in the space said.
Some 50 groups have signed a letter expressing strong opposition to a bill that would allow workplace wellness programs to collect employees' genetic information.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
The company launched an updated version of its Face2Gene software suite earlier this month at the American Society of Human Genetics annual meeting.
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.